Antidote
NOVEMBER 15, 2024
Looking toward 2025, clinical trial sponsors must plan now and rethink their patient recruitment strategies to stay ahead of evolving technologies, regulations, and shifting patient expectations. The landscape of clinical trials is changing rapidly, and recruitment will require a more agile, data-driven, and patient-centric approach than ever before.
Bio Pharma Dive
NOVEMBER 15, 2024
At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending and maintaining lines of sight to the clinic.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
NOVEMBER 15, 2024
Syros Pharmaceuticals announced that its cancer drug tamibarotene failed to meet its primary endpoint in the SELECT-MDS-1 Phase III trial. The trial was evaluating the drug in combination with the chemotherapy azacitidine for the treatment of newly diagnosed patients with higher-risk myelodysplastic syndrome (HR-MDS) who harbor overexpression of the RARA (retinoic acid receptor alpha) gene.
Pharmaceutical Technology
NOVEMBER 15, 2024
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa combined with Velcade, plus Revlimid, plus dexamethasone (VRd) for treating newly diagnosed multiple myeloma (MM).
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
XTalks
NOVEMBER 15, 2024
Longboard Pharmaceuticals recently announced the launch of its Phase III DEEp OCEAN study to assess the potential of bexicaserin, a drug aimed at reducing seizures linked to developmental and epileptic encephalopathies (DEEs). This study, deemed the first of its kind by Chad Orevillo, Longboard’s executive vice president, marks a critical step in addressing a previously underserved need in epilepsy treatment.
Bio Pharma Dive
NOVEMBER 15, 2024
Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke with BioPharma Dive about how the company came together.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
NOVEMBER 15, 2024
The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first Lyfgenia revenue and Leerink built up its M&A team.
Pharmaceutical Technology
NOVEMBER 15, 2024
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
Bio Pharma Dive
NOVEMBER 15, 2024
“Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel hosted by BioPharma Dive.
Pharmaceutical Technology
NOVEMBER 15, 2024
The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only nilotinib formulation that does not require mealtime restrictions, to treat chronic myeloid leukaemia (CML).
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
NOVEMBER 15, 2024
Explore valuable tips and strategies to enhance clinical trials by prioritising and improving the overall patient experience. Learn how to optimise patient recruitment, retention, and satisfaction through effective communication and personalised support.
Pharmaceutical Technology
NOVEMBER 15, 2024
Revenue for the mpox vaccine is down compared to last year however its travel vaccine business grew by 21%.
XTalks
NOVEMBER 15, 2024
UK-based med tech company LivaNova announced positive results from its OSPREY clinical study evaluating the LivaNova aura6000 system for the treatment of obstructive sleep apnea (OSA) using targeted nerve stimulation. The study successfully met its primary safety and efficacy endpoints. The aura6000 is an implantable hypoglossal neurostimulator designed to treat adult patients with moderate to severe OSA.
Pharmaceutical Technology
NOVEMBER 15, 2024
The two-day Oncology event will see industry experts from across the clinical trial space holding talks on subjects from AI to business
XTalks
NOVEMBER 15, 2024
Virtual healthcare provider Omada Health recently published findings from a consumer survey that aimed to gain insights into the experiences of users taking GLP-1 receptor agonists. The attitudinal survey, which included 1,000 non-Omada members ages 21 to 75, examined the impact of GLP-1 medications across the patient journey, exploring people’s emotions and experiences before, during and after using the weight loss treatments.
Pharmaceutical Technology
NOVEMBER 15, 2024
MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the latter’s new investigational programmed cell death 1 (PD-1)/vascular endothelial growth factor (VEGF) bispecific antibody, LM-299.
Fierce Pharma
NOVEMBER 15, 2024
Azurity Pharmaceuticals has earned an FDA approval for Danziten, a new formulation of Novartis’ chronic myeloid leukemia (CML) blockbuster Tasigna.
Outsourcing Pharma
NOVEMBER 15, 2024
Genesis Therapeutics has secured $200 million funding from NVentures, NVIDIAâs venture capital arm.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
CTTI (Clinical Trials Transformation Initiative)
NOVEMBER 15, 2024
A new CTTI publication published in the Journal of Clinical and Translational Science highlights the qualitative research findings that informed recommendations to facilitate the integration of clinical trials into clinical practice. By integrating key elements of clinical trials—such as patient identification and data collection—into everyday practice, research efforts can be streamlined to reduce duplication of activities.
ProRelix Research
NOVEMBER 15, 2024
Patients are the heart of all clinical trials ranging from recruitment, retention, protocol adherence, assessments, and safety data, making it necessary to ensure that patients are well-informed on trial protocol, […] The post Clinical Trials: Information for Patients and Caregivers appeared first on ProRelix Research.
Pharmaceutical Commerce
NOVEMBER 15, 2024
The latest news for pharma industry insiders.
Pharma Marketing Network
NOVEMBER 15, 2024
In the fast-paced world of pharmaceutical marketing, effective marketing networking can be the golden ticket to your next career boost or major deal. But with tight budgets and an evolving landscape, how can pharma professionals effectively connect in 2025 without breaking the bank? Let’s dive into ten strategies that are both impactful and affordable.
Pharmaceutical Commerce
NOVEMBER 15, 2024
The collaboration ultimately benefits oncology patients, as life science companies will be able to access their cancer journey data more efficiently.
XTalks
NOVEMBER 15, 2024
Pfizer released a new respiratory syncytial virus (RSV) vaccine TV commercial, titled “Your Moments Are Worth Protecting: Celebration” as part of its ongoing campaign to raise awareness about the importance of vaccination against RSV. In the 30-second commercial, Pfizer showcases a series of celebratory moments, appearing to be taken by everyday people on their cell phones.
Pharmaceutical Commerce
NOVEMBER 15, 2024
In the first part of this roundtable discussion, a panel of subject matter experts introduce themselves, while discussing why the pharma supply chain sees value in this technology and why its use has fluctuated over the past decade.
XTalks
NOVEMBER 15, 2024
Leading medical devices and medical supplies company Baxter International announced it will restart a second production line for intravenous (IV) fluids at its North Cove, North Carolina facility impacted by Hurricane Helene. The facility, a major supplier of IV fluids and Baxter’s largest manufacturing plant, was severely affected by the recent hurricane, leading to significant disruptions in production.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Drug Channels
NOVEMBER 15, 2024
Today’s guest post comes from Kala Bala, SVP, Enterprise Access & Data Expertise, MMIT, a Norstella company and Dinesh Kabaleeswaran, SVP, Advisory Services at MMIT, a Norstella company. The authors outline the challenges that manufacturers face when integrating internal and external datasets to build market access and commercialization strategies.
Fierce Pharma
NOVEMBER 15, 2024
With multiple drugmakers already announcing a slew of radiopharmaceutical moves this year, France’s Orano Med is doubling down on the nuclear medicine craze. | Orano Med—developing targeted alpha therapies for cancer—kicked off construction of a 250 million euro plant in the Bessines-sur-Gartempe commune of France. Dubbed the Advanced Thorium Extraction Facility, the new 7,000-square-meter site is slated to manufacture thorium-228, a precursor of lead-212, for radioligand therapies.
Pharma Marketing Network
NOVEMBER 15, 2024
In the world of pharmaceutical marketing, social media marketing strategies are more than a trend; they’re a necessity. But with strict regulations and evolving consumer expectations, how do pharma brands navigate the digital landscape effectively? The answer lies in a mix of proven strategies designed for this unique sector. Table of Contents Sr# Headings 1 Know Your Audience and Their Needs 2 Leverage Branded and Unbranded Content 3 Engage Responsibly and Transparently 4 Utilize Influenc
Fierce Pharma
NOVEMBER 15, 2024
Thursday’s appointment from president-elect Donald Trump made it official: noted vaccine skeptic Robert Francis Kennedy Jr. (RFK Jr.) will be asked to serve as the next U.S. | President-elect Donald Trump's choice for HHS secretary could pose risk to vaccine makers' top lines, as evidenced by sinking share prices after the appointment.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
52 
Let's personalize your content